Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term expression. Found 374 abstracts

no pagination
Zhang Y, Wang J, Xie J, Yang D, Han G, Zhang Y, Fu Q. The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma. Eur Surg. 2015 Oct;47(5):248-53.
Betancourt A, Mobley JA, Wang J, Jenkins S, Chen DQ, Kojima K, Russo J, Lamartiniere CA. Alterations in the Rat Serum Proteome Induced by Prepubertal Exposure to Bisphenol A and Genistein. Journal of Proteome Research. 2014 Mar;13(3):1502-14.   PMCID: PMC 3993963
Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG, Cairns P. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biology & Therapy. 2014 Mar;15(3):329-41.   PMCID: PMC3974843
Betancourt AM, Wang J, Jenkins S, Mobley J, Russo J, Lamartiniere CA. Altered Carcinogenesis and Proteome in Mammary Glands of Rats after Prepubertal Exposures to the Hormonally Active Chemicals Bisphenol A and Genistein. Journal of Nutrition. 2012 Jul;142(7):1382S-1388S.   PMCID: PMC3374674
Bodurka DC, Deavers MT, Tian CQ, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system. Cancer. 2012 Jun;118(12):3087-94.   PMCID: *
Brewster BL, Rossiello F, French JD, Edwards SL, Wong M, Wronski A, Whiley P, Waddell N, Chen XW, Bove B, Hopper JL, John EM, Andrulis I, Daly M, Volorio S, Bernard L, Peissel B, Manoukian S, Barile M, Pizzamiglio S, Verderio P, Spurdle AB, Radice P, Godwin AK, Southey MC, Brown MA, Peterlongo P. Identification of fifteen novel germline variants in the BRCA1 3 ' UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Human Mutation. 2012 Dec;33(12):1665-75.
Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Yang DH, Vispute SG, Jiang WQ, Chen SD, Chen ZS. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Science. 2012 Aug;103(8):1531-7.   PMCID: PMC3407321[Available on 2013/8/1]
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Dec;127(3):538-43.   PMCID: PMC3568489
Damania D, Roy HK, Subramanian H, Weinberg DS, Rex DK, Goldberg MJ, Muldoon J, Cherkezyan L, Zhu YJ, Bianchi LK, Shah D, Pradhan P, Borkar M, Lynch H, Backman V. Nanocytology of Rectal Colonocytes to Assess Risk of Colon Cancer Based on Field Cancerization. Cancer Research. 2012 Jun;72(11):2720-7.   PMCID: NIHMS370344
De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clinical Breast Cancer. 2012 Aug;12(4):264-9.   PMCID: not NIH funded
Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Shani Paluch S, Kaufman B, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Cajal TR, Stavropoulou AV, Benitez J, Hamann U, Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Garcia EB, Hoogerbrugge N, Jager A, van der Luijt RB, Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Leone M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys S, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, DeMars LR, DiSilvestro P, Rodriguez G, Toland AE, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Ramus SJ, Sucheston L, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H, Aittomaki K, Simard J, Spurdle AB, Beesley J, Chen XQ, Tomlinson GE, Weitzel J, Garber JE, Olopade OI, Rubinstein WS, Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor N, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H, Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SL. A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention. 2012 Aug;21(8):1362-70.   PMCID: PMC3415567
Doss M, Kolb HC, Zhang JJ, Belanger MJ, Stubbs JB, Stabin MG, Hostetler ED, Alpaugh RK, von Mehren M, Walsh JC, Haka M, Mocharla VP, Yu JQ. Biodistribution and Radiation Dosimetry of the Integrin Marker F-18-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans. Journal of Nuclear Medicine. 2012 May;53(5):787-95.
Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer. 2012 Feb;106(4):748-55.   PMCID: PMC3322945
Engel I, Zhao M, Kappes D, Taniuchi I, Kronenberg M. The transcription factor Th-POK negatively regulates Th17 differentiation in V alpha 14i NKT cells. Blood. 2012 Nov;120(23):4524-32.   PMCID: PMC3512232
Hayashi N, Nakamura S, Tokuda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. International Journal of Clinical Oncology. 2012 Feb;17(1):55-62.   PMCID: *
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. Journal of Surgical Oncology. 2012 Jul;106(1):24-30.   PMCID: PMC3370134
Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Paligo M, Aretini P, Kantala J, Aroer B, Von Wachenfeldt A, Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Nathanson KL, Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Cajal TR, Tsitlaidou M, Benitez J, Gilbert M, Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Blok MJ, Nelen MR, van den Ouweland AM, Seynaeve C, van der Luijt RB, Devilee P, Easton DF, Peock S, Frost D, Platte R, Ellis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin A, Bove B, Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P, Coupier I, Peyrat JP, Vennin P, Muller D, Fricker JP, Venat-Bouvet L, Johannsson O, Isaacs C, Schmutzler R, Wappenschmidt B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Preisler-Adams S, Simard J, Soucy P, Durocher F, Chenevix-Trench G, Beesley J, Chen X, Rebbeck T, Couch F, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Bonanni B, Fortuzzi S, Peissel B, Szabo C, Mai PL, Loud JT, Lubinski J. Association of PHB 1630 C > T and MTHFR 677 C > T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer. 2012 Jun;106(12):2016-24.   PMCID: PMC3388557
Lee CK, Marschner IC, Simes RJ, Voysey M, Egleston B, Hudes G, de Souza P. Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research. 2012 Jun;18(11):3188-96.   PMCID: Not NIH funded
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecologic Oncology. 2012 Nov;127(2):345-50.
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecologic Oncology. 2012 Nov;127(2):345-50.   PMCID: PMC3518448
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term expression

expression tumors chemotherapy carcinoma cancer risk proteins carcinogenesis Epidermal growth factor receptor Endometrial cancer-Mutation-Lapatinib-Tyrosine kinase inhibitor disease receptor her2 epidermal-growth-factor therapy proliferation tumor lung-cancer breast-cancer cell lung-cancer marker kinase inhibitor pik3ca mutations factor receptor advanced breast-cancer gefitinib progression thymidine kinase 1 randomized phase-iii prognostic indicators 1989 entice rl-statistics in medicine-v8-p431 marrow clinical utility cell RCC cells rna ANGIOGENESIS KIDNEY CANCER micrometastases cetuximab her-2 mutations ovarian cancer risk PATHWAYS breast cancer BRCA1-3 ' UTR-microRNAs disparities analysis family registry genetic-variation Endometrial cancer Aflibercept-VEGF Trap-Toxicity-Fibroblast growth factor binding protein hur combination clear Prognostic factors CT growth subfamily-b member-1 STEM-CELLS prognosis DIFFERENTIATION natural-killer sites fecal occult blood Circulating tumor cells Bone metastases-Lymphocytopenia-Metastatic breast cancer-PET tumor-suppressor gene ror-gamma-t mutational gene mucosa in-utero exposure family colon cancer mtor BRCA1 genistein positive Trastuzumab susceptibility metabolism amino-acid polymorphism Oncology insulin aurora kinase A breast-cancer cells chromosome-17 TISSUE KRAS mutation disorder strength rapamycin vegf RNA a gene human-diseases mouse serum statistical-model folate status progression-free survival mrp7 lymphomas centrosome amplification drug-resistance database search 1st-line treatment neoplasms colon-cancer colorectal carcinoma c-erbb-2 protein overexpression PHB 1630 C > T polymorphism 2 mutation carriers-MTHFR 677 C > T polymorphism-breast universal grading system carcinomas women mammalian target rats phosphodiesterase-5 erectile Serum HER2 nonpolyposis colorectal-cancer BPA software panitumumab copy number induced apoptosis neu susceptibility gene bone metastases homeostasis p53 abcc10 common mutation Breast neoplasm doxorubicin survival CARCINOMA region lineage commitment selection recurrence surrogate extracellular domain IDENTIFICATION produce il-17 prohibitin 3'-untranslated proteomics annexin-ii menstrual factors oncoprotein braf bevacizumab gynecologic-oncology-group trastuzumab-based therapy t-cells
Last updated on Wednesday, September 06, 2017